Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.29

-0.30%
HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$281.55M
EPS-2.2700
P/E Ratio-1.45
Earnings Date08/06/2026

lrmr

Long Term Investments

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Competitors Analysis of Long Term Investments

LRMR · NASDAQ
CompanyLong Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
0.00
N/AN/AN/A
2.70M
-70.4%-53.2%5.2%
770.00K
N/AN/AN/A
19.00M
-26.8%-43.5%N/A
419.00K
N/A-5.2%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
0.00
N/AN/AN/A
71.44M
N/AN/AN/A
Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.29, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

Intrinsic Value
Current Price: $3.29